XML 86 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Goodwill and Other Intangible Assets
 3 Months Ended
Apr. 03, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2019
$
22,712.5

Attributable to 2020 acquisitions
11,497.2

Adjustments due to finalization of purchase price allocations
0.7

Foreign currency translation and other
(484.9
)
Balance, April 3, 2020
$
33,725.5

The carrying value of goodwill by segment is summarized as follows ($ in millions):
 
April 3, 2020
 
December 31, 2019
Life Sciences
$
24,703.0

 
$
13,471.8

Diagnostics
6,740.1

 
6,901.2

Environmental & Applied Solutions
2,282.4

 
2,339.5

Total
$
33,725.5

 
$
22,712.5


The increase in the goodwill balance of the Life Sciences segment in the three-month period ended April 3, 2020 is a result of the Cytiva Acquisition. Refer to Note 3 for more detail. The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three-month period ended April 3, 2020.
Finite-lived intangible assets are amortized over their legal or estimated useful life. The following summarizes the gross carrying value and accumulated amortization for each major category of intangible assets ($ in millions):
 
April 3, 2020
 
December 31, 2019
 
Gross Carrying Amount
 
Accumulated Amortization
 
Gross Carrying Amount
 
Accumulated Amortization
Finite-lived intangibles:
 
 
 
 
 
 
 
Patents and technology
$
10,035.5

 
$
(970.1
)
 
$
2,712.7

 
$
(934.1
)
Customer relationships and other intangibles
7,915.4

 
(2,672.4
)
 
6,367.4

 
(2,612.3
)
Total finite-lived intangibles
17,950.9

 
(3,642.5
)
 
9,080.1

 
(3,546.4
)
Indefinite-lived intangibles:
 
 
 
 
 
 
 
Trademarks and trade names
4,204.2

 
—

 
4,216.0

 
—

Total intangibles
$
22,155.1

 
$
(3,642.5
)
 
$
13,296.1

 
$
(3,546.4
)

During the three-month period ended April 3, 2020, the Company acquired finite-lived intangible assets, consisting primarily of developed technology and customer relationships, with a weighted average life of 14 years as a result of the Cytiva Acquisition. Refer to Note 3 for additional information on the intangible assets acquired.
The Company identified impairment triggers during the first quarter of 2020 which resulted in the impairment of certain long-lived assets, including a trade name. The Company recorded impairment charges totaling $8 million in the three-month period ended April 3, 2020 related to these long-lived assets.